Investor Presentaiton
POTENTIAL KEY EVENTS 2023
New since last update
Lilly
Phase 3 Initiations
Basal Insulin-Fc for type 2 diabetes (QWINT-1)
Regulatory Submissions
Tirzepatide for chronic weight management (US/EU)
Tirzepatide for chronic weight management (H2H vs semaglutide 2.4 mg) Lebrikizumab for atopic dermatitis (J)
✓ Retatrutide for chronic weight management
+
✓ Orforglipron for chronic weight management
Orforglipron for type 2 diabetes
Remternetug for early Alzheimer's disease (efficacy trials)
Phase 3 Data Disclosures
Donanemab for early Alzheimer's disease
Tirzepatide for chronic weight management (SURMOUNT-2)
Tirzepatide for chronic weight management (SURMOUNT-3)
Tirzepatide for chronic weight management (SURMOUNT-4)
Mirikizumab for Crohn's disease
Abemaciclib for castrate-resistant prostate cancer (CYCLONE-2)
Pirtobrutinib for CLL prior BTKI (BRUIN CLL-321)
Empagliflozin for chronic kidney disease 1 (US/EU/J)
Donanemab for early Alzheimer's disease 2 (US/EU/J)
Pirtobrutinib for MCL prior BTKi (J)
Pirtobrutinib for CLL prior BTKi and BCL213
Regulatory Actions
Donanemab for early Alzheimer's disease³ (US)
Lebrikizumab for atopic dermatitis (US/EU)
Mirikizumab for ulcerative colitis (US/EU/J
Pirtobrutinib for MCL prior BTKI (US/EU)
Empagliflozin for chronic kidney disease 1 (US/EU/J)
Tirzepatide for chronic weight management (US)
Pirtobrutinib for CLL prior BTKi and BCL2i3
1 In collaboration with Boehringer Ingelheim
2 Under the traditional approval pathway
3 Under the FDA Accelerated Approval Program
Not for promotional use
2023 Q2 EARNINGS
19View entire presentation